Drug intelligence / Profile preview

cilomilast

Development stage: Phase 3
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Ophthalmic

Overview

Cilomilast is an orally active, second-generation small molecule drug developed as a selective phosphodiesterase 4 (PDE4) inhibitor. It was primarily investigated for the treatment of respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma. Cilomilast acts by inhibiting PDE4, an enzyme that degrades cyclic AMP in pro-inflammatory and immune cells; this inhibition leads to anti-inflammatory effects targeting bronchoconstriction, mucus hypersecretion, and airway remodeling associated with COPD. The drug demonstrated reasonable efficacy in clinical trials but was discontinued due to its side effect profile and has never been marketed[1][2][3][5].

Brand names: Ariflo
Other names: cilomilast

Targets

PDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)PDE4D (Phosphodiesterase 4D)

Beyond the preview

Go deeper on cilomilast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cilomilast.

Explore the full profile